What is William Blair’s Estimate for TENX FY2028 Earnings?

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Analysts at William Blair issued their FY2028 EPS estimates for Tenax Therapeutics in a research report issued on Wednesday, May 14th. William Blair analyst M. Phipps anticipates that the specialty pharmaceutical company will post earnings of ($1.85) per share for the year. William Blair has a “Outperform” rating on the stock. The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($0.88) per share.

Tenax Therapeutics (NASDAQ:TENX) last posted its quarterly earnings data on Wednesday, May 14th. The specialty pharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.20.

A number of other analysts also recently issued reports on the stock. Leerink Partners set a $20.00 price objective on shares of Tenax Therapeutics in a report on Monday, March 10th. StockNews.com began coverage on shares of Tenax Therapeutics in a report on Friday. They issued a “sell” rating on the stock. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Tenax Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $18.00.

Tenax Therapeutics Stock Up 3.3%

NASDAQ TENX opened at $5.89 on Friday. Tenax Therapeutics has a 12-month low of $2.77 and a 12-month high of $7.89. The company has a market capitalization of $24.43 million, a PE ratio of -2.38 and a beta of 1.92. The firm’s 50 day moving average is $5.86 and its 200-day moving average is $5.90.

Institutional Trading of Tenax Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its position in Tenax Therapeutics by 32.4% during the fourth quarter. Geode Capital Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock worth $151,000 after acquiring an additional 5,964 shares in the last quarter. ADAR1 Capital Management LLC raised its position in Tenax Therapeutics by 98.1% during the first quarter. ADAR1 Capital Management LLC now owns 68,741 shares of the specialty pharmaceutical company’s stock worth $450,000 after acquiring an additional 34,048 shares in the last quarter. Two Sigma Investments LP bought a new stake in Tenax Therapeutics during the fourth quarter worth $84,000. Millennium Management LLC bought a new stake in Tenax Therapeutics during the fourth quarter worth $166,000. Finally, Janus Henderson Group PLC bought a new stake in Tenax Therapeutics during the fourth quarter worth $1,026,000. 1.67% of the stock is owned by institutional investors.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.